Article Details

Eli Lilly's Ebglyss: A Promising Alternative for Dupixent-Resistant Atopic Dermatitis Patients

Retrieved on: 2024-10-28 19:56:11

Tags for this article:

Click the tags to see associated articles and topics

Eli Lilly's Ebglyss: A Promising Alternative for Dupixent-Resistant Atopic Dermatitis Patients. View article details on hiswai:

Excerpt

Leerink Partners analyst David Risinger has maintained their bullish stance on LLY stock, giving a Buy rating today. David Risinger's rat...

Article found on: markets.businessinsider.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up
Book a Demo